➤ Subscribe for Complete Access

Flexible subscription options to meet your unique needs…

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Merck
Boehringer Ingelheim
Express Scripts
Moodys

Last Updated: November 27, 2021

DrugPatentWatch Database Preview

PFIZER Company Profile


Email this page to a colleague

« Back to Dashboard

Summary for PFIZER

Drugs and US Patents for PFIZER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer STREPTOMYCIN SULFATE streptomycin sulfate INJECTABLE;INJECTION 060111-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try it Free ⤷  Try it Free
Pfizer MEDROL methylprednisolone TABLET;ORAL 011153-005 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try it Free ⤷  Try it Free
Pfizer SINEQUAN doxepin hydrochloride CAPSULE;ORAL 016798-007 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Try it Free ⤷  Try it Free
Pfizer GLUCOTROL glipizide TABLET;ORAL 017783-003 May 11, 1993 DISCN Yes No ⤷  Try it Free ⤷  Try it Free
Pfizer VISTARIL hydroxyzine hydrochloride INJECTABLE;INJECTION 011111-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PFIZER

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer Pharms ACCURETIC hydrochlorothiazide; quinapril hydrochloride TABLET;ORAL 020125-001 Dec 28, 1999 4,743,450*PED ⤷  Try it Free
Pfizer ESTRING estradiol INSERT, EXTENDED RELEASE;VAGINAL 020472-001 Apr 26, 1996 4,871,543 ⤷  Try it Free
Pfizer TIKOSYN dofetilide CAPSULE;ORAL 020931-003 Oct 1, 1999 6,124,363 ⤷  Try it Free
Pfizer TROVAN trovafloxacin mesylate TABLET;ORAL 020759-001 Dec 18, 1997 6,187,341 ⤷  Try it Free
Pfizer MINIPRESS XL prazosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 019775-001 Jan 29, 1992 4,765,989 ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for PFIZER drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 5 mg and 10 mg ➤ Subscribe 2005-06-21
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe 2011-06-17
➤ Subscribe Oral Suspension 100 mg/5 mL ➤ Subscribe 2009-08-03
➤ Subscribe Injection 2 mg/mL, 100 mL bag ➤ Subscribe 2009-12-29
➤ Subscribe Tablets 5 mg ➤ Subscribe 2016-11-07
➤ Subscribe Delayed-release Tablets 50 mg/0.2 mg ➤ Subscribe 2009-06-29
➤ Subscribe Extended-release Tablets 11 mg ➤ Subscribe 2016-11-07
➤ Subscribe Capsules 20 mg, 40 mg, 60 mg and 80 mg ➤ Subscribe 2005-02-07
➤ Subscribe Capsules 75 mg, 100 mg and 125 mg ➤ Subscribe 2019-02-04
➤ Subscribe Capsules 0.125 mg, 0.25 mg, and 0.5 mg ➤ Subscribe 2014-05-01
➤ Subscribe Tablets 600 mg ➤ Subscribe 2005-12-21
➤ Subscribe Injection 2 mg/mL, 300 mL bag ➤ Subscribe 2009-09-01
➤ Subscribe Tablets 1 g ➤ Subscribe 2005-08-23
➤ Subscribe Delayed-release Tablets 75 mg/0.2 mg ➤ Subscribe 2008-11-28
➤ Subscribe Extended-release Tablets 4 mg and 8 mg ➤ Subscribe 2012-10-31
➤ Subscribe Injection 20 mg/mL, 2 mL and 5 mL vials ➤ Subscribe 2004-07-26

Supplementary Protection Certificates for PFIZER Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2822953 C02822953/01 Switzerland ⤷  Try it Free PRODUCT NAME: LORLATINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66941 19.02.2020
0454511 99C0009 Belgium ⤷  Try it Free PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
2316456 1790064-8 Sweden ⤷  Try it Free PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REG. NO/DATE: EU/1/14/988 20150330
2316456 17C1058 France ⤷  Try it Free PRODUCT NAME: NALTREXONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE NALTREXONE ET,BUPROPION OU SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE BUPROPION; REGISTRATION NO/DATE: EU/1/14/988 20150330
1666481 1790038-2 Sweden ⤷  Try it Free PRODUCT NAME: TOFACITINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE CITRATE SALT; REG. NO/DATE: EU/1/17/1178 20170324
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
McKesson
Express Scripts
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.